Clinical study of loracarbef

We evaluated the clinical efficacy and safety of loracarbef (LCBF), a new carbacephem antibiotic.LCBF was administrated to 9 patients with respiratory infections and one with pyelonephritis.The patients received the drug orally for 2 to 11 days at a dose of 600 mg/day. Clinical efficacy was good in...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 41; no. Supplement3; pp. 574 - 576
Main Authors Wada, Kouichi, Sega, Hiroyuki, Kawasima, Takasi, Tukada, Hiroki, Arakawa, Masaaki
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1993
Subjects
loracarbef
Online AccessGet full text

Cover

More Information
Summary:We evaluated the clinical efficacy and safety of loracarbef (LCBF), a new carbacephem antibiotic.LCBF was administrated to 9 patients with respiratory infections and one with pyelonephritis.The patients received the drug orally for 2 to 11 days at a dose of 600 mg/day. Clinical efficacy was good in 9 and unknown in 1.Side effects included exanthema in 2 patients, abdominal pain in 1, and nausea and diarrhea in 1.No abnormal laboratory findings were observed after the administration of LCBF.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.41.Supplement3_574